Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA: 600566)

Market Cap	25.94B
Revenue (ttm)	8.92B
Net Income (ttm)	2.78B
Shares Out	921.70M
EPS (ttm)	3.03
PE Ratio	9.30
Forward PE	9.02
Dividend	1.30 (4.47%)
Ex-Dividend Date	n/a

Volume	5,333,864
Open	29.08
Previous Close	29.08
Day's Range	27.93 - 29.28
52-Week Range	23.85 - 45.18
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 26, 2025

About Hubei Jumpcan Pharmaceutical

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Fei Cao
• Employees: 5,230
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600566

Financial Performance

In 2023, Hubei Jumpcan Pharmaceutical's revenue was 9.65 billion, an increase of 7.32% compared to the previous year's 9.00 billion. Earnings were 2.82 billion, an increase of 30.04%.